NervGen Pharma Corp Asset Resilience Ratio
NervGen Pharma Corp asset resilience ratio. NervGen Pharma Corp (NGEN) has an Asset Resilience Ratio of 0.25% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See NervGen Pharma Corp defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of NervGen Pharma Corp (2023–2024)
Asset resilience ratio of NervGen Pharma Corp from 2023 to 2024. This chart shows how NervGen Pharma Corp's Asset Resilience Ratio has changed over time. Read NervGen Pharma Corp debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down NervGen Pharma Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see NGEN total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 0% |
| Short-term Investments | CA$33.23K | 0.25% |
| Total Liquid Assets | CA$33.23K | 0.25% |
Asset Resilience Insights
- Limited Liquidity: NervGen Pharma Corp maintains only 0.25% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
NervGen Pharma Corp Industry Peers by Asset Resilience Ratio
Compare NervGen Pharma Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
NervGen Pharma Corp Asset Resilience Ratio by Year (2023–2024)
NervGen Pharma Corp asset resilience ratio by year from 2023 to 2024. The table below shows the annual Asset Resilience Ratio data for NervGen Pharma Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.50% | CA$97.23K ≈ $70.34K |
CA$19.49 Million ≈ $14.10 Million |
-- |
| 2023-12-31 | 0.00% | CA$0.00 ≈ $0.00 |
CA$13.24 Million ≈ $9.57 Million |
-- |
About NervGen Pharma Corp
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's… Read more